Keytruda (pembrolizumab) is an immunotherapy drug that falls under the category of immune checkpoint inhibitors. It works by blocking the PD-1 (programmed death receptor-1) pathway, which cancer cells often exploit to evade the immune system. By inhibiting this pathway, Keytruda helps restore the immune system’s ability to recognize and attack cancer cells.
